Is Orforglipron Approved Yet?
FDA status, obesity filing timeline, Phase 3 data from ATTAIN-1, and what happens next for Eli Lilly’s oral non-peptide GLP-1 receptor agonist.
Update History ▾
Initial publication
No. As of March 9, 2026, orforglipron is not approved by the FDA or any other regulatory agency. Eli Lilly reported positive Phase 3 obesity data from the ATTAIN-1 trial in August 2025, showing 12.4% average weight loss at 72 weeks with the 36 mg dose. Orforglipron remains in the regulatory-review stage. No FDA submission date or expected approval timeline has been publicly disclosed.
Janoshik-verified, HPLC ≥99.2% purity. Retatrutide Pen 30 mg from AED 1,000/pen. Ships from Dubai.
- Orforglipron is not approved as of March 9, 2026.
- Positive Phase 3 data from ATTAIN-1 reported August 2025: 12.4% weight loss at 72 weeks (36 mg dose).
- Orforglipron is an oral non-peptide GLP-1 agonist — no food or water dosing restrictions.
- The Wegovy pill (oral semaglutide 25 mg) is the only approved oral GLP-1 for obesity in the US.
- No FDA submission date has been publicly announced by Eli Lilly.
| Item | Status (March 9, 2026) |
|---|---|
| FDA Approval | Not approved |
| Clinical Stage | Positive Phase 3 data (ATTAIN-1) |
| Best Weight-Loss Figure | 12.4% at 72 weeks (36 mg dose) |
| Developer | Eli Lilly |
| Drug Type | Oral non-peptide GLP-1 receptor agonist |
| Dosing | Once daily, no food/water restrictions |
| FDA Submission Date | Not publicly disclosed |
| Expected Approval Date | Not publicly disclosed |
What is Orforglipron?
Orforglipron is Eli Lilly’s once-daily oral non-peptide GLP-1 receptor agonist being developed for obesity and type 2 diabetes. The non-peptide structure is the key differentiator — unlike peptide-based oral GLP-1 drugs such as the Wegovy pill and Rybelsus (oral semaglutide), orforglipron does not require fasting before dosing or restrictions on food and water intake after administration. For a detailed comparison of all oral GLP-1 compounds, see Oral Obesity Drugs in 2026.
Lilly positions orforglipron as an oral GLP-1 that eliminates the formulation constraints that have historically limited peptide-based oral drugs. This practical advantage is distinct from mechanism of action — orforglipron activates the same GLP-1 receptor as semaglutide, but delivers it in a structurally different oral format.
What Did the ATTAIN-1 Phase 3 Trial Show?
In August 2025, Eli Lilly reported positive Phase 3 obesity data from the ATTAIN-1 trial. The headline figures: the highest dose (36 mg once daily) lowered body weight by an average of 12.4% at 72 weeks — equivalent to 27.3 pounds — versus 0.9% for placebo.
The ATTAIN-1 trial also showed improvements in cardiometabolic risk factors alongside weight reduction. Lilly stated that the results support advancement toward regulatory submissions, but no specific submission date has been publicly disclosed.
| Feature | Orforglipron | Wegovy Pill |
|---|---|---|
| Status (March 2026) | Not approved (Phase 3 complete) | FDA approved; US launched |
| Drug Type | Non-peptide GLP-1 agonist | Peptide-based oral semaglutide |
| Mechanism | GLP-1 receptor agonist | GLP-1 receptor agonist |
| Developer | Eli Lilly | Novo Nordisk |
| Best Weight-Loss Figure | 12.4% at 72 weeks (ATTAIN-1) | 16.6% (OASIS 4, adherence estimand) |
| Dosing Restrictions | None — no food/water restrictions | Empty stomach, limited water, 30-min fast |
What Happens Next?
Three developments define the near-term path for orforglipron:
1. Regulatory filing. Eli Lilly has not publicly disclosed when it will submit a New Drug Application (NDA) to the FDA for orforglipron in obesity. The positive ATTAIN-1 data support advancement, but the submission timeline remains undisclosed.
2. Additional Phase 3 readouts. The ATTAIN clinical program includes multiple trials across obesity and type 2 diabetes. Subsequent readouts will expand the efficacy and safety dataset.
3. Competitive positioning. The Wegovy pill is already approved and commercially available. Orforglipron’s competitive case rests on its non-peptide format and the practical dosing advantage it offers. The question is whether that convenience factor translates into meaningful differentiation at the regulatory and commercial level. For a direct efficacy comparison, see Retatrutide vs Orforglipron. Track all pipeline milestones on the obesity drug approval tracker.
Why Does This Matter Now?
Orforglipron is one of the most closely watched investigational obesity drugs in the pipeline because it represents a structurally different approach to oral GLP-1 therapy. If approved, it would be the first non-peptide oral GLP-1 agonist for obesity — a meaningful distinction from the peptide-based Wegovy pill.
The practical implications are significant. Peptide-based oral drugs require specific dosing conditions — empty stomach, small amounts of water, waiting periods before eating — that affect real-world adherence. A non-peptide oral GLP-1 without those restrictions could change the convenience calculus for patients and prescribers. For verified research peptide suppliers, see our best research peptides 2026 guide.
Our Research Standards
This article cites peer-reviewed studies, FDA filings, and ClinicalTrials.gov data. All claims are cross-referenced against primary sources. We update articles when new trial data or regulatory decisions are published. Read our editorial policy →
- Eli Lilly. Orforglipron Phase 3 obesity results — ATTAIN-1. August 2025. investor.lilly.com
- Eli Lilly. What to know about orforglipron. lilly.com
- Novo Nordisk. FDA approves Wegovy pill (oral semaglutide 25 mg). December 2025. novonordisk.com
- Novo Nordisk. Annual Report 2025: Innovation and therapeutic focus. annualreport.novonordisk.com
Retatrutide Pen 30 mg
99.262% HPLC purity, Janoshik Analytical. 300 clicks per pen, ships from Dubai.
Order Retatrutide Pen →